Skip to Content
Merck
CN
  • Community-based management and outcome of omphalitis in newborns in Karachi, Pakistan.

Community-based management and outcome of omphalitis in newborns in Karachi, Pakistan.

JPMA. The Journal of the Pakistan Medical Association (2014-01-08)
Farah Naz Qamar, Shiyam Sundar Tikmani, Fatima Mir, Anita Kazmi Mehdi Zaidi
ABSTRACT

To describe the clinical profile and outcome in newborns with omphalitis managed with home or clinic-based therapy. The descriptive study was conducted from September 2004 to August 2007 in three low-income communities in Karachi, Pakistan. Newborns with omphalitis detected by community health workers through active surveillance were referred to local clinics. Those with physician-confirmed omphalitis were treated for 7 days with topical gentian violet or oral cephalexin (as monotherapy) or topical gentian violet and oral cephalexin (combination therapy) at physician discretion, or injectable therapy (procaine penicillin and gentamicin) if clinical signs of sepsis were also present and family refused hospital referral. Follow-up was at 48-72 hours and 7 days. SPSS 16 was used for statistical analysis. Among 1083 newborns with omphalitis, 578 (53.4%) had peri-umbilical cellulitis without purulent discharge; 365 (33.7%) had purulent discharge (with or without cellulitis); and 140 (13%) had omphalitis with sepsis Review of outcome data at one week showed that among 943 newborns without signs of sepsis, 938 (99.5%) had improved; 2 (0.2%) died, and 2 (0.2%) were lost to follow-up. There were 5 (3.6%) therapy failures, among 140 newborns with omphalitis and sepsis managed with parenteral antibiotics at 48 hours, but 139 (99.2%) had improved by one week, while 1 (0.8%) died. In resource-constrained environments, omphalitis can be managed in the community with minimal need for hospital referral. Further research to define optimal therapeutic regimens is needed.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Cephalexin hydrate, first-generation cephalosporin antibiotic
Sigma-Aldrich
Gentian Violet, meets USP testing specifications
Sigma-Aldrich
Crystal Violet, suitable for microscopy
Sigma-Aldrich
Crystal Violet, ACS reagent, ≥90.0% anhydrous basis
Sigma-Aldrich
Crystal Violet, S. No.: 785
Supelco
Crystal Violet, VETRANAL®, analytical standard
Sigma-Aldrich
Crystal Violet, certified by the BSC
Sigma-Aldrich
Crystal Violet Solution, 1%, aqueous solution
Supelco
Cefalexin, VETRANAL®, analytical standard